利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.02 秒)

    Human pyrimidine receptor
    1.
    发明授权
    Human pyrimidine receptor 有权
    人嘧啶受体

    公开(公告)号：US07270966B2

    公开(公告)日：2007-09-18

    申请号：US10753695

    申请日：2004-01-08

    申请人： Didier Communi ,  Marc Parmentier ,  Jean-Marie Boeynaems ,  Sabine Pirotton

    发明人： Didier Communi ,  Marc Parmentier ,  Jean-Marie Boeynaems ,  Sabine Pirotton

    IPC分类号： G01N33/53 ,  C12Q1/68

    CPC分类号： C07K14/705 ,  A01K2217/05 ,  A01K2217/075 ,  C12N2310/14

    摘要： This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphosphate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent. This means that the receptor according to the invention in presence of these agonists presents a functional response (preferably the accumulation of Inositol triphosphate (IP3), diacylglycerol (DAG), or calcium ions) to lower concentration of pyrimidine nucleotides, preferably uridine triphosphate, than to purine nucleotides or a more important functional response to similar concentration of pyrimidine nucleotide than to purine nucleotide

    摘要翻译： 本发明提供了对嘌呤核苷酸优先选择嘧啶核苷酸优选尿苷三磷酸的受体。 对嘌呤核苷酸优先选择嘧啶核苷酸的受体是指嘧啶核苷酸和嘌呤核苷酸不具有同等活性和等同性的受体。 这意味着在这些激动剂存在下，根据本发明的受体具有功能性反应（优选三聚磷酸肌醇（IP3），二酰基甘油（DAG）或钙离子）的积累）以降低嘧啶核苷酸浓度，优选尿苷三磷酸 嘌呤核苷酸或与嘌呤核苷酸相似浓度的嘧啶核苷酸的更重要的功能反应

    P2Y4 Receptor transgenic and knockout non-human mammals
    2.
    发明申请
    P2Y4 Receptor transgenic and knockout non-human mammals 审中-公开
    P2Y4受体转基因和敲除非人哺乳动物

    公开(公告)号：US20070044166A1

    公开(公告)日：2007-02-22

    申请号：US11483432

    申请日：2006-07-07

    申请人： Didier Communi ,  Sabine Pirotton ,  Marc Parmentier ,  Jean-Marie Boeynaems

    发明人： Didier Communi ,  Sabine Pirotton ,  Marc Parmentier ,  Jean-Marie Boeynaems

    IPC分类号： A01K67/027

    CPC分类号： C07K14/705 ,  A01K2217/05 ,  A01K2217/075 ,  C12N2310/14

    摘要： This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphosphate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent. This means that the receptor according to the invention in presence of these agonists presents a functional response (preferably the accumulation of Inositol triphosphate (IP3), diacylglycerol (DAG), or calcium ions) to lower concentration of pyrimidine nucleotides, preferably uridine triphosphate, than to purine nucleotides or a more important functional response to similar concentration of pyrimidine nucleotide than to purine nucleotide

    摘要翻译： 本发明提供了对嘌呤核苷酸优先选择嘧啶核苷酸优选尿苷三磷酸的受体。 对嘌呤核苷酸优先选择嘧啶核苷酸的受体是指嘧啶核苷酸和嘌呤核苷酸不具有同等活性和等同性的受体。 这意味着在这些激动剂存在下，根据本发明的受体具有功能性反应（优选三聚磷酸肌醇（IP3），二酰基甘油（DAG）或钙离子）的积累）以降低嘧啶核苷酸浓度，优选尿苷三磷酸 嘌呤核苷酸或与嘌呤核苷酸相似浓度的嘧啶核苷酸的更重要的功能反应

    P2Y4 antibodies
    3.
    发明授权
    P2Y4 antibodies 有权
    P2Y4抗体

    公开(公告)号：US07312317B2

    公开(公告)日：2007-12-25

    申请号：US10811198

    申请日：2004-03-26

    申请人： Didier Communi ,  Jean-Marie Boeynaems ,  Marc Parmentier ,  Sabine Pirotton

    发明人： Didier Communi ,  Jean-Marie Boeynaems ,  Marc Parmentier ,  Sabine Pirotton

    IPC分类号： C07K16/18 ,  A61K39/395

    CPC分类号： C07K14/705 ,  A01K2217/05 ,  A01K2217/075 ,  C12N2310/14

    摘要： This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphosphate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent. This means that the receptor according to the invention in presence of these agonists presents a functional response (preferably the accumulation of Inositol triphosphate (IP3), diacylglycerol (DAG), or calcium ions) to lower concentration of pyrimidine nucleotides, preferably uridine triphosphate, than to purine nucleotides or a more important functional response to similar concentration of pyrimidine nucleotide than to purine nucleotide.

    摘要翻译： 本发明提供了对嘌呤核苷酸优先选择嘧啶核苷酸优选尿苷三磷酸的受体。 对嘌呤核苷酸优先选择嘧啶核苷酸的受体是指嘧啶核苷酸和嘌呤核苷酸不具有同等活性和等同性的受体。 这意味着在这些激动剂存在下，根据本发明的受体具有功能性反应（优选三聚磷酸肌醇（IP3），二酰基甘油（DAG）或钙离子）的积累）以降低嘧啶核苷酸浓度，优选尿苷三磷酸 嘌呤核苷酸或与嘌呤核苷酸相似浓度的嘧啶核苷酸的更重要的功能反应。

    PHARMACEUTICAL FORMULATION FOR ALLERGEN PREPARATION
    5.
    发明申请
    PHARMACEUTICAL FORMULATION FOR ALLERGEN PREPARATION 审中-公开
    用于过敏制剂的药物制剂

    公开(公告)号：US20100278880A1

    公开(公告)日：2010-11-04

    申请号：US12810536

    申请日：2008-12-30

    申请人： Thierry Legon ,  Sabine Pirotton ,  Gael Placier ,  Gilles Kergoat

    发明人： Thierry Legon ,  Sabine Pirotton ,  Gael Placier ,  Gilles Kergoat

    IPC分类号： A61K9/00 ,  A61K39/35

    CPC分类号： A61K39/35 ,  A61K39/36 ,  A61K2039/542 ,  A61K2039/6087

    摘要： Method for the production of a purified extract of natural allergens comprising the steps of extracting a natural source of allergens comprising allergenic proteins, purifying of said extract to remove non-protein components denaturating said purified extract, said purified denaturated extract comprising proteins, wherein the most abundant (w/w) proteins, forming together at least 60% (w/w) of all proteins, are at least two proteins, and all proteins represent at least 60% (w/w) of the dry weight of the purified denaturated extract or a method for the production of a purified extract of natural allergens comprising the steps of hydrolysing a denaturated allergen purifying said allergen hydrolysate to remove peptides with a molecular weight above 10,000 Da and below 1,000 Da in order to obtain a purified hydrolysate where 70%, more preferably 80% of the peptides are between 10,000 Da and 1,000 Da, in the form of an starch based pellet.

    摘要翻译： 用于生产天然过敏原纯化提取物的方法，包括以下步骤：提取包含过敏原蛋白质的天然过敏原来源，纯化所述提取物以除去使所述纯化提取物变性的非蛋白质组分，所述纯化的变性提取物包含蛋白质，其中最多 含有至少60％（w / w）的所有蛋白质的丰富的（w / w）蛋白质是至少两种蛋白质，所有蛋白质代表纯化变性干重的至少60％（w / w） 提取物或生产天然过敏原纯化提取物的方法，包括以下步骤：将纯化所述变应原水解产物的变性过敏原水解除去分子量高于10,000Da且低于1,000Da的肽，以获得纯化的水解产物，其中70％ 更优选80％的肽在10,000Da和1,000Da之间，以淀粉基丸的形式。

    Method for The Production of Hydrolyzed Allergen
    7.
    发明申请
    Method for The Production of Hydrolyzed Allergen 审中-公开
    水解过敏原生产方法

    公开(公告)号：US20090324650A1

    公开(公告)日：2009-12-31

    申请号：US12308859

    申请日：2007-06-28

    申请人： Thierry Legon ,  Sabine Pirotton ,  Gael Placier ,  Gilles Kergoat

    发明人： Thierry Legon ,  Sabine Pirotton ,  Gael Placier ,  Gilles Kergoat

    IPC分类号： A61K39/35 ,  C07K1/00 ,  C07K1/14 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K1/30 ,  C07K14/00 ,  C07K1/20 ,  A61P37/08

    CPC分类号： A61K39/35 ,  A61K39/36 ,  A61K2039/542 ,  C07K14/415 ,  C12P21/06

    摘要： A method for the production of a purified extract of natural allergens comprising the steps of a) extracting a natural source of allergens comprising allergenic proteins to form an extract, b) purifying of said extract to remove non-protein components to form a purified extract c) denaturating said purified extract to form a purified denaturated extract, said purified denaturated extract comprising proteins, wherein the most abundant (w/w) proteins, forming together at least 60% (w/w) of all proteins, are at least two proteins, and all proteins represent at least 60% (w/w) of the dry weight of the purified denaturated extract and a method for the production of a purified extract of natural allergens comprising the steps of a) hydrolysing a denaturated allergen to form an allergen hydrolysate, b) purifying said allergen hydrolysate to remove peptides with a molecular weight above 10,000 Da and below 1,000 Da in order to obtain a purified hydrolysate where 70%, more preferably 80% of the peptides are between 10,000 Da and 1,000 Da.

    摘要翻译： 一种用于生产天然过敏原纯化提取物的方法，包括以下步骤：a）提取包含过敏原蛋白质的天然过敏原来源以形成提取物，b）纯化所述提取物以除去非蛋白质组分以形成纯化的提取物c ）使所述纯化的提取物变性以形成纯化的变性提取物，所述纯化的变性提取物包含蛋白质，其中形成所有蛋白质至少60％（w / w）的最丰富的（w / w）蛋白质是至少两种蛋白质 ，并且所有蛋白质代表纯化的变性提取物的干重的至少60％（w / w），以及用于生产纯化的天然过敏原提取物的方法，包括以下步骤：a）水解变性变应原以形成变应原 水解物，b）纯化所述变应原水解产物以除去分子量高于10,000Da且低于1,000Da的肽，以获得纯化的水解产物，其中70％，更优选80％ 肽在10,000Da和1,000Da之间。